# US 2024/0173426 A1 · Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0173426 A1
- Document ID: US20240173426A1
- Status: Published application
- Kind: A1
- Application number: 18/509,030
- Filed: 2023-11-14
- Published: 2024-05-30
- Earliest claimed: 2022-11-14
- Assignees: Regeneron Pharmaceuticals, Inc.
- Applicants: Regeneron Pharmaceuticals, Inc.
- Inventors: Jeffery Haines; Keith Crosby; Yan Yang; Christopher Daly; William Olson; Tammy T. Huang; Drew Dudgeon; Robert Babb
- Web page: https://patentgrep.com/patent/US20240173426A1

## CPC

- A61K 47/6849: {the antibody targeting a receptor, a cell surface antigen or a cell surface determinant}
- A61K 47/6807: {the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense}
- A61K 47/6811: {the drug being a protein or peptide, e.g. transferrin or bleomycin}
- A61K 47/6815: {Enzymes}
- A61K 47/6889: {Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment}
- A61K 47/6929: {the form being a nanoparticle, e.g. an immuno-nanoparticle}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- C07K 16/2863: {against receptors for growth factors, growth regulators}
- C12N 9/226: {Class 2 CAS enzyme complex, e.g. single CAS protein}
- C12N 15/11: DNA or RNA fragments; Modified forms thereof (DNA or RNA not used in recombinant technology, C07H21/00); {Non-coding nucleic acids having a biological activity}
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/77: Internalization into the cell
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K 2317/94: Stability, e.g. half-life, pH, temperature or enzyme-resistance
- C07K 2319/00: Fusion polypeptide
- C12N 2310/14: interfering nucleic acids [NA]
- C12N 2310/20: involving clustered regularly interspaced short palindromic repeats [CRISPR]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The present invention provides, in part, protein-drug conjugates comprising an anti-fibroblast growth factor receptor 3 (FGFR3) (e.g., human FGFR3) antigen-binding protein (e.g., scFv, Fab) conjugated to a molecular cargo (e.g., polynucleotides, polypeptides, liposomes or lipid nanoparticles) for delivery of the molecular cargo to a targeted tissue (e.g., brain). Methods for treating various diseases or disorders, such as neurological diseases, with the conjugates are provided.

## Claims

### Claim 1

A protein-drug conjugate comprising an antigen-binding protein that binds specifically to fibroblast growth factor receptor 3 (FGFR3) and is conjugated to a molecular cargo.

### Claim 2 (depends on 1)

The protein-drug conjugate of claim 1 wherein the antigen binding protein comprises an antibody or antigen-binding fragment thereof.

### Claim 3 (depends on 1, 2)

The protein-drug conjugate of claim 1 or claim 2, wherein the protein drug conjugate comprises a heavy chain variable region (HCVR or VH) and/or a light chain variable region (LCVR or VL).

### Claim 4 (depends on 3)

The protein-drug conjugate of claim 3, wherein the antigen-binding protein is selected from a humanized antibody or antigen binding fragment thereof, human antibody or antigen binding fragment thereof, murine antibody or antigen binding fragment thereof, chimeric antibody or antigen binding fragment thereof, monovalent Fab′, divalent Fab2, F(ab)′3 fragments, single-chain fragment variable (scFv), bis-scFv, (scFv)2, diabody, minibody, nanobody, triabody, tetrabody, disulfide stabilized Fv protein (dsFv), single-domain antibody (sdAb), Ig NAR, single heavy chain antibody, bispecific antibody or biding fragment thereof, bi-specific T-cell engager (BITE), trispecific antibody, or chemically modified derivatives thereof.

### Claim 5 (depends on 3)

The protein-drug conjugate of claim 3, wherein the antigen-binding protein comprises a fragment antigen-binding region (Fab).

### Claim 6 (depends on 3)

The protein-drug conjugate of claim 3, wherein the antigen-binding protein comprises a single chain fragment variable (scFv).

### Claim 7 (depends on 6)

The protein-drug conjugate of claim 6, wherein the scFv comprises domains arranged in the following orientation from N-terminus to C-terminus: HCVR-LCVR.

### Claim 8 (depends on 6)

The protein-drug conjugate of claim 6, wherein the scFv comprises domains arranged in the following orientation from N-terminus to C-terminus: LCVR-HCVR.

### Claim 9 (depends on 6, 7, 8)

The protein-drug conjugate of any one of claims 6-8, wherein the scFv variable regions are connected by a linker.

### Claim 10 (depends on 9)

The protein-drug conjugate of claim 9, wherein the linker is a peptide linker.

### Claim 11 (depends on 10)

The protein-drug conjugate of claim 10, wherein the peptide linker is -(GGGGS)n—(SEQ ID NO: 321); wherein n is 1-10.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The protein-drug conjugate of any one of claims 1-11 which comprises:
(i) a HCVR that comprises the HCDR1, HCDR2 and HCDR3 of a HCVR comprising the amino acid sequence set forth in SEQ ID NO: 2, 22, 42, 62, 82, 102, 122, 140, 159, 169, 179, 199 or 219 (or a variant thereof);
and/or
(ii) a LCVR that comprises the LCDR1, LCDR2 and LCDR3 of a LCVR comprising the amino acid sequence set forth in SEQ ID NO: 10, 30, 50, 70, 90, 110, 130, 148, 187, 207, or 227 (or a variant thereof).

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The protein-drug conjugate of any one of claims 1-12 which comprises:
(1) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 2 (or a variant thereof); and a LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 10 (or a variant thereof);
(2) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 22; and a LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 30 (or a variant thereof);
(3) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 42; and a LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 50 (or a variant thereof);
(4) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 62 (or a variant thereof); and a LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 70 (or a variant thereof);
(5) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 82 (or a variant thereof); and a LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 90 (or a variant thereof);
(6) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 102 (or a variant thereof); and a LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 110 (or a variant thereof);
(7) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 122 (or a variant thereof); and LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 130 (or a variant thereof);
(8) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 140 (or a variant thereof); and a LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 148 (or a variant thereof);
(9) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 159 (or a variant thereof); and LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 148 (or a variant thereof);
(10) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 169 (or a variant thereof); and LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 148 (or a variant thereof);
(11) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 179 (or a variant thereof); and LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 187 (or a variant thereof);
(12) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 199 (or a variant thereof); and LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 207 (or a variant thereof); or
(13) a HCVR comprising the HCDR1, HCDR2 and HCDR3 of a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 219 (or a variant thereof); and LCVR comprising the LCDR1, LCDR2 and LCDR3 of a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 227 (or a variant thereof).

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The protein-drug conjugate of any one of claims 1-13 which comprises:
(a) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 4 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 6 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 8 (or a variant thereof); and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 12 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 14 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 16 (or a variant thereof);
(b) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 24 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 26 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 28 (or a variant thereof); and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 36 (or a variant thereof);
(c) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 44 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 46 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 48 (or a variant thereof); and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 52 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 54 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 56 (or a variant thereof);
(d) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 64 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 66 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 68 (or a variant thereof); and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 72 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 74 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 76 (or a variant thereof);
(e) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 84 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 86 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 88 (or a variant thereof); and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 92 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 94 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 96 (or a variant thereof);
(f) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 104 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 106 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 108 (or a variant thereof); and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 112 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 114 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 116 (or a variant thereof);
(g) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 124 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 126 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 128 (or a variant thereof), and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 132 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 134; (or a variant thereof)
(h) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 142 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 144 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 146 (or a variant thereof), and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 150 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 14 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 153 (or a variant thereof);
(i) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 161 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 163 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 165 (or a variant thereof), and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 150 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 14 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 153 (or a variant thereof);
(j) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 171 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 173 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 175 (or a variant thereof), and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 150 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 14 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 153 (or a variant thereof);
(k) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 181 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 183 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 185 (or a variant thereof), and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 189 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 191 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 193 (or a variant thereof);
(l) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 201 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 203 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 205 (or a variant thereof), and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 209 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 211 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 213 (or a variant thereof);
and/or (m) a HCVR that comprises:
an HCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 221 (or a variant thereof),
an HCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 223 (or a variant thereof), and
an HCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 225 (or a variant thereof), and
a LCVR that comprises:
an LCDR1 comprising the amino acid sequence set forth in SEQ ID NO: 32 (or a variant thereof),
an LCDR2 comprising the amino acid sequence set forth in SEQ ID NO: 34 (or a variant thereof), and
an LCDR3 comprising the amino acid sequence set forth in SEQ ID NO: 76 (or a variant thereof).

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The protein-drug conjugate of any one of claims 1-14 which comprises:
(i) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 2 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 10 (or a variant thereof);
(ii) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 22 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 30 (or a variant thereof);
(iii) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 42 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 50 (or a variant thereof);
(iv) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 62 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 70 (or a variant thereof);
(v) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 82 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 90 (or a variant thereof);
(vi) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 102 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 110 (or a variant thereof);
(vii) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 122 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 130 (or a variant thereof);
(viii) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 140 (or a variant thereof); and a LCVR that the amino acid sequence set forth in SEQ ID NO: 148 (or a variant thereof);
(ix) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 159 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 148 (or a variant thereof);
(x) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 169 (or a variant thereof); and LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 148 (or a variant thereof);
(xi) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 179 (or a variant thereof); and a LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 187 (or a variant thereof);
(xii) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 199 (or a variant thereof); and LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 207 (or a variant thereof);
or
(xiii) a HCVR that comprises the amino acid sequence set forth in SEQ ID NO: 219 (or a variant thereof); and LCVR that comprises the amino acid sequence set forth in SEQ ID NO: 227 (or a variant thereof).

### Claim 16 (depends on 1, 2, 3)

The protein-drug conjugate of any one of claims 1-3, and 12-15, which comprises:
(a) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 18, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 20;
(b) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 38, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 40;
(c) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 58, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 60;
(d) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 78, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 80;
(e) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 98, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 100;
(f) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 118, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 120;
(g) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 136, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 138;
(h) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 155, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 157;
(i) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 167, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 157;
(j) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 177, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 157;
(k) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 195, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 197;
(I) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 215, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 217;
and/or
(m) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 229, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 231.

### Claim 17 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16)

The protein-drug conjugate of any one of claims 1-16, wherein the antigen-binding protein binds specifically to FGFR3b and/or FGFR3c.

### Claim 18 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17)

The protein-drug conjugate of any one of claims 1-17, wherein the antigen-binding protein that binds specifically to human FGFR3b and/or FGFR3c.

### Claim 19 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)

The protein-drug conjugate of any one of claims 1-18, wherein the antigen-binding protein binds specifically to FGFR3b.

### Claim 20 (depends on 17, 18, 19)

The protein-drug conjugate of any one of claims 17-19, wherein the FGFR3b is monomeric and/or dimeric FGFR3b.

### Claim 21 (depends on 17, 18, 19, 20)

The protein-drug conjugate of any one of claims 17-20, wherein the FGFR3b is monomeric FGFR3b.

### Claim 22 (depends on 17, 18, 19, 20)

The protein-drug conjugate of any one of claims 17-20, wherein the FGFR3b is dimeric FGFR3b.

### Claim 23 (depends on 22)

The protein-drug conjugate of claim 22, which comprises:
(a) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 18, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 20;
(b) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 38, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 40;
(c) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 58, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 60;
(d) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 78, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 80;
(e) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 98, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 100;
(f) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 118, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 120;
(g) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 136, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 138;
(h) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 167, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 157;
(i) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 177, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 157;
(j) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 195, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 197;
(k) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 215, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 217;
and/or
(l) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 229, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 231.

### Claim 24 (depends on 17, 18)

The protein-drug conjugate of any one of claims 17-18, wherein the FGFR3c is monomeric and/or dimeric FGFR3c.

### Claim 25 (depends on 24)

The protein-drug conjugate of any one of claim 24, wherein the FGFR3c is monomeric FGFR3c.

### Claim 26 (depends on 25)

The protein-drug conjugate of claim 25, which comprises:
(a) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 98, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 100;
(b) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 155, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 157;
(c) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 177, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 157;
(d) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 195, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 197;
(e) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 215, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 217;
and/or
(f) a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 229, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 231.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26)

The protein-drug conjugate of any one of claims 1-26, wherein the antigen-binding protein binds specifically to both FGFR3b and FGFR3c.

### Claim 28 (depends on 18, 19, 20, 21, 22, 23, 27)

The protein-drug conjugate of any one of claims 18-23 and 27, wherein the antigen-binding protein binds to human FGFR3b with a KD of about 1λ10−7 M or a stronger affinity.

### Claim 29 (depends on 28)

The protein-drug conjugate of claim 28, wherein the antigen-binding protein binds to human FGFR3b with a KD of about 1×10−8 M or a stronger affinity.

### Claim 30 (depends on 18, 24, 25, 26, 27)

The protein-drug conjugate of any one of claims 18 and 24-27, wherein the antigen-binding protein binds to human FGFR3c with a KD of about 1×10−7 M or a stronger affinity.

### Claim 31 (depends on 30)

The protein-drug conjugate of claim 30, wherein the antigen-binding protein binds to human FGFR3c with a KD of about 1×10−8 M or a stronger affinity.

### Claim 32 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)

The protein-drug conjugate of any one of claims 1-20, which comprises a heavy chain that comprises the amino acid sequence set forth in SEQ ID NO: 18, and a light chain that comprises the amino acid sequence set forth in SEQ ID NO: 20.

### Claim 33 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The protein-drug conjugate of any one of claims 1-11, wherein the antigen-binding protein binds to the same epitope on FGFR3 as an antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1-1.

### Claim 34 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The protein-drug conjugate of any one of claims 1-11, wherein the antigen-binding protein competes for binding to FGFR3 with an antibody comprising an HCVR/LCVR amino acid sequence pair as set forth in Table 1-1.

### Claim 35

A protein-drug conjugate comprising an antigen-binding protein that binds specifically to fibroblast growth factor receptor 3 (FGFR3), wherein the antigen-binding protein is conjugated to a molecular cargo and comprises an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof binds to one or more epitopes of FGFR3 selected from:
a. an epitope comprising the sequence GPTVVVVK (SEQ ID NO: 378) and/or an epitope comprising the sequence TQR;
b. an epitope comprising the sequence ADVR (SEQ ID NO: 376) and/or an epitope comprising the sequence IGVAEK (SEQ ID NO: 377);
c. an epitope comprising the sequence HCKVY (SEQ ID NO: 379), and/or an epitope comprising the sequence KSWISE (SEQ ID NO: 380), and/or an epitope comprising the sequence ADVR (SEQ ID NO: 376);
d. an epitope comprised within or overlapping with the sequence GPTVVVVK (SEQ ID NO: 378) and/or an epitope comprised within or overlapping with the sequence TQR;
e. an epitope comprised within or overlapping with the sequence ADVR (SEQ ID NO: 376) and/or an epitope comprised within or overlapping with the sequence IGVAEK (SEQ ID NO: 377); and
f. an epitope comprised within or overlapping with the sequence HCKVY (SEQ ID NO: 379), and/or an epitope comprised within or overlapping with the sequence KSWISE (SEQ ID NO: 380), and/or an epitope comprised within or overlapping with the sequence ADVR (SEQ ID NO: 376).

### Claim 36 (depends on 35)

The protein-drug conjugate of claim 35, wherein the antibody or antigen-binding fragment thereof binds to one or more epitopes of FGFR3 selected from:
a. an epitope consisting of the sequence GPTVWVK (SEQ ID NO: 378) and/or an epitope consisting of the sequence TQR;
b. an epitope consisting of the sequence ADVR (SEQ ID NO: 376) and/or an epitope consisting of the sequence IGVAEK (SEQ ID NO: 377); and
c. an epitope consisting of the sequence HCKVY (SEQ ID NO: 379), and/or an epitope consisting of the sequence KSWISE (SEQ ID NO: 380), and/or an epitope consisting of the sequence ADVR (SEQ ID NO: 376).

### Claim 37

A protein-drug conjugate comprising an antigen-binding protein that binds specifically to fibroblast growth factor receptor 3 (FGFR3), wherein the antigen-binding protein is conjugated to a molecular cargo and comprises an antibody or antigen-binding fragment thereof, wherein the antibody or antigen-binding fragment thereof binds to one or more epitopes of FGFR3 selected from:
a. an epitope comprising the sequence SCPPPGGGPMGPTVVVVKDGTGLVPSER (SEQ ID NO: 363) and/or an epitope comprising the sequence YSCRQRLTQRVL (SEQ ID NO: 364;
b. an epitope comprising the sequence LLAVPAAN (SEQ ID NO: 365), and/or an epitope comprising the sequence VLERSPHRPILQAG (SEQ ID NO: 366) and/or an epitope comprising the sequence YVTVLKSWISE (SEQ ID NO: 367) and/or or an epitope comprising the sequence ADVRLR (SEQ ID NO: 368) and/or an epitope comprising the sequence LCRATNFIGVAEKAFW (SEQ ID NO: 369);
c. an epitope comprising the sequence GQQEQLVFGSGDAVE (SEQ ID NO: 370) and/or an epitope comprising the sequence VLVGPQRL (SEQ ID NO: 371);
d. an epitope comprising the sequence VLERSPHRPILQAG (SEQ ID NO: 372) and/or an epitope comprising the sequence HCKVYSDAQP (SEQ ID NO: 373) and/or an epitope comprising the sequence YVTVLKSWISESVEADVRLR (SEQ ID NO: 374) and/or an epitope comprising the sequence LCRATNFIGVAEKAF (SEQ ID NO: 375);
e. an epitope comprised within or overlapping with the sequence SCPPPGGGPMGPTVWVKDGTGLVPSER (SEQ ID NO: 363) and/or an epitope comprised within or overlapping with the sequence YSCRQRLTQRVL (SEQ ID NO: 364);
f. an epitope comprised within or overlapping with the sequence LLAVPAAN (SEQ ID NO: 365, and/or an epitope comprised within or overlapping with the sequence VLERSPHRPILQAG (SEQ ID NO: 366) and/or an epitope comprised within or overlapping with the sequence YVTVLKSWISE (SEQ ID NO: 367) and/or or an epitope comprised within or overlapping with the sequence ADVRLR (SEQ ID NO: 368) and/or an epitope comprised within or overlapping with the sequence LCRATNFIGVAEKAFW (SEQ ID NO: 369;
g. an epitope comprised within or overlapping with the sequence GQQEQLVFGSGDAVE (SEQ ID NO: 370) and/or an epitope comprised within or overlapping with the sequence VLVGPQRL (SEQ ID NO: 371); and
h. an epitope comprised within or overlapping with the sequence VLERSPHRPILQAG (SEQ ID NO: 372) and/or an epitope comprised within or overlapping with the sequence HCKVYSDAQP (SEQ ID NO: 373) and/or an epitope comprised within or overlapping with the sequence YVTVLKSWISESVEADVRLR (SEQ ID NO: 374) and/or an epitope comprised within or overlapping with the sequence LCRATNFIGVAEKAF (SEQ ID NO: 375.

### Claim 38 (depends on 37)

The protein-drug conjugate of claim 37, wherein the antibody or antigen-binding fragment thereof binds to one or more epitopes of FGFR3 selected from:
a. an epitope consisting of the sequence SCPPPGGGPMGPTVVVVKDGTGLVPSER (SEQ ID NO: 363) and/or an epitope consisting of the sequence YSCRQRLTQRVL (SEQ ID NO: 364);
b. an epitope consisting of the sequence LLAVPAAN (SEQ ID NO: 365), and/or an epitope consisting of the sequence VLERSPHRPILQAG (SEQ ID NO: 366) and/or an epitope consisting of the sequence YVTVLKSWISE (SEQ ID NO: 367) and/or or an epitope consisting of the sequence ADVRLR (SEQ ID NO: 368) and/or an epitope consisting of the sequence LCRATNFIGVAEKAFW (SEQ ID NO: 369);
c. an epitope consisting of the sequence GQQEQLVFGSGDAVE (SEQ ID NO: 370) and/or an epitope consisting of the sequence VLVGPQRL (SEQ ID NO: 371); and
d. an epitope consisting of the sequence VLERSPHRPILQAG (SEQ ID NO: 372) and/or an epitope consisting of the sequence HCKVYSDAQP (SEQ ID NO: 373) and/or an epitope consisting of the sequence YVTVLKSWISESVEADVRLR (SEQ ID NO: 374) and/or an epitope consisting of the sequence LCRATNFIGVAEKAF (SEQ ID NO: 375).

### Claim 39 (depends on 35, 36, 37, 38)

The protein-drug conjugate of any one of claims 35-38, wherein the antigen-binding protein is selected from a humanized antibody or antigen binding fragment thereof, human antibody or antigen binding fragment thereof, murine antibody or antigen binding fragment thereof, chimeric antibody or antigen binding fragment thereof, monovalent Fab′, divalent Fab2, F(ab)′3 fragments, single-chain fragment variable (scFv), bis-scFv, (scFv)2, diabody, bivalent antibody, one-armed antibody, minibody, nanobody, triabody, tetrabody, disulfide stabilized Fv protein (dsFv), single-domain antibody (sdAb), Ig NAR, single heavy chain antibody, bispecific antibody or biding fragment thereof, bi-specific T-cell engager (BITE), trispecific antibody, or chemically modified derivatives thereof.

### Claim 40 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The protein-drug conjugate of any one of claims 1-39, wherein said molecular cargo is conjugated to:
(i) a HCVR of the antigen-binding protein,
(ii) a LCVR of the antigen-binding protein,
(iii) a heavy chain of the antigen-binding protein, and/or
(iv) a light chain of the antigen-binding protein.

### Claim 41 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40)

The protein-drug conjugate of any one of claims 1-40, wherein said molecular cargo is conjugated to the antigen-binding protein via a glutamine residue and/or a lysine residue.

### Claim 42 (depends on 41)

The protein-drug conjugate of claim 41, wherein the glutamine residue is:
(i) introduced to the N-terminus and/or C-terminus of a heavy chain of the antigen-binding protein,
(ii) introduced to the N-terminus and/or C-terminus of a light chain of the antigen-binding protein,
(iii) naturally present in a CH2 or CH3 domain of the antigen-binding protein,
(iv) introduced to the antigen-binding protein by modifying one or more amino acids, and/or
(v) Q295 or mutated from N297 to Q297 (N297Q).

### Claim 43 (depends on 41, 42)

The protein-drug conjugate of claim 41 or 42, wherein the antigen-binding protein comprises a glutamine-containing tag, and the molecular cargo is conjugated to the antigen-binding protein via a glutamine residue of the glutamine-containing tag.

### Claim 44 (depends on 43)

The protein-drug conjugate of claim 43, wherein the glutamine-containing tag comprises an amino acid sequence selected from the group consisting of LLQGG (SEQ ID NO: 290), LLQG (SEQ ID NO: 291), LSLSQG (SEQ ID NO: 292), GGGLLQGG (SEQ ID NO: 293), GLLQG (SEQ ID NO: 294), LLQ, GSPLAQSHGG (SEQ ID NO: 295), GLLQGGG (SEQ ID NO: 296), GLLQGG (SEQ ID NO: 297), GLLQ (SEQ ID NO: 298), LLQLLQGA (SEQ ID NO: 299), LLQGA (SEQ ID NO: 300), LLQYQGA (SEQ ID NO: 301), LLQGSG (SEQ ID NO: 302), LLQYQG (SEQ ID NO: 303), LLQLLQG (SEQ ID NO: 304), SLLQG (SEQ ID NO: 305), LLQLQ (SEQ ID NO: 306), LLQLLQ (SEQ ID NO: 307), and LLQGR (SEQ ID NO: 308).

### Claim 45 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44)

The protein-drug conjugate of any one of claims 1-44, wherein the antigen-binding protein and the molecular cargo are conjugated via a linker.

### Claim 46 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45)

The protein-drug conjugate of any one of claims 1-45, wherein the molecular cargo comprises a polynucleotide molecule, a polypeptide molecule, a carrier, a viral particle, a viral capsid protein, or a small molecule.

### Claim 47 (depends on 46)

The protein-drug conjugate of claim 46, wherein the molecular cargo comprises a polynucleotide molecule.

### Claim 48 (depends on 47)

The protein-drug conjugate of claim 47, wherein the polynucleotide molecule is an interfering nucleic acid molecule, a guide RNA, a ribozyme, an aptamer, a mixmer, a multimer, or an mRNA.

### Claim 49 (depends on 48)

The protein-drug conjugate of claim 48, wherein the interfering nucleic acid molecule is an siRNA, an shRNA, a miRNA, an antisense oligonucleotide, or a gapmer.

### Claim 50 (depends on 48, 49)

The protein-drug conjugate of claim 48 or 49, wherein the interfering nucleic acid molecule is an siRNA.

### Claim 51 (depends on 50)

The protein-drug conjugate of claim 50, wherein the siRNA comprises a sense strand of 21 nucleotides in length.

### Claim 52 (depends on 50, 51)

The protein-drug conjugate of claim 50 or 51, wherein the siRNA comprises an antisense strand of 23 nucleotides in length.

### Claim 53 (depends on 50, 51, 52)

The protein-drug conjugate of any one of claims 50-52, wherein the siRNA comprises two phosphorothioate linkages at the first and second internucleoside linkages at the 5′ end of the sense strand.

### Claim 54 (depends on 50, 51, 52, 53)

The protein-drug conjugate of any one of claims 50-53, wherein the siRNA comprises two phosphorothioate linkages at the first and second internucleoside linkages at the 3′ and/or 5′ ends of the antisense strand.

### Claim 55 (depends on 48, 49)

The protein-drug conjugate of claim 48 or 49, wherein the interfering nucleic acid molecule is an antisense oligonucleotide.

### Claim 56 (depends on 48)

The protein-drug conjugate of claim 48, wherein the polynucleotide molecule is a guide RNA.

### Claim 57 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56)

The protein-drug conjugate of any one of claims 48-56, wherein the polynucleotide molecule targets a gene or gene product associated with a neurological disease and/or disorder.

### Claim 58 (depends on 57)

The protein-drug conjugate of claim 57, wherein the gene is APOE4, GFAP, MECP2, AQP4, or STAT3.

### Claim 59 (depends on 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58)

The protein-drug conjugate of any one of claims 48-58, wherein the polynucleotide molecule comprises one or more modified nucleotides.

### Claim 60 (depends on 46)

The protein-drug conjugate of claim 46, wherein the molecular cargo comprises a polypeptide molecule.

### Claim 61 (depends on 60)

The protein-drug conjugate of claim 60, wherein the polypeptide molecule is an enzyme, a neuroprotective molecule, or an antigen-binding protein that binds to a target other than FGFR3.

### Claim 62 (depends on 60, 61)

The protein-drug conjugate of claim 60 or 61, wherein the polypeptide molecule is associated with a neurological disease and/or disorder.

### Claim 63 (depends on 62)

The protein-drug conjugate of claim 62, wherein the polypeptide molecule is a protective ApoE isoform or variant, ATPase 13A2 (encoded by ATP13A2), sulfatase modifying factor 1 (encoded by SUMF1), fragile X messenger ribonucleoprotein (FMRP) (encoded by FMR1), or glutamate transporter-1 (encoded by GLT1).

### Claim 64 (depends on 63)

The protein-drug conjugate of claim 63, wherein the protective ApoE isoform or variant is ApoE2, ApoE Christchurch, or ApoE Jacksonville.

### Claim 65 (depends on 62)

The protein-drug conjugate of claim 62, wherein the polypeptide molecule is a neurotrophic factor, an antibody or antibody fragment, an antibody receptor fusion protein, or a suppressor of cytokine signaling.

### Claim 66 (depends on 65)

The protein-drug conjugate of claim 65, wherein the neurotrophic factor is ciliary neurotrophic factor (CNTF), brain derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), or insulin-like growth factor 1 (IGF).

### Claim 67 (depends on 65)

The protein-drug conjugate of claim 65, wherein the antibody receptor fusion protein is anti-amyloid beta Gas6 fusion protein.

### Claim 68 (depends on 65)

The protein-drug conjugate of claim 65, wherein the suppressor of cytokine signaling is suppressor of cytokine signaling 3 (Socs3).

### Claim 69 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68)

The protein-drug conjugate of any one of claims 1-68, wherein the molecular cargo is conjugated to the antigen-binding protein at a drug-to-antibody ratio (DAR) of a least 1 to at least 10.

### Claim 70 (depends on 69)

The protein-drug conjugate of claim 69, wherein the molecular cargo is conjugated to the antigen-binding protein at a DAR of 1, 2, 3, or 4.

### Claim 71 (depends on 69, 70)

The protein-drug conjugate of claim 69 or 70, wherein the molecular cargo is conjugated to the antigen-binding protein at a DAR of 2.

### Claim 72 (depends on 69, 70)

The protein-drug conjugate of claim 69 or 70, wherein the molecular cargo is conjugated to the antigen-binding protein at a DAR of 4.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The protein-drug conjugate of any one of claims 1-72 for use in treating or preventing a neurological disease or disorder.

### Claim 74 (depends on 57, 62)

The protein-drug conjugate of any one of claims 57, 62, and 73, wherein the neurological disease or disorder is a neurodegenerative disease, a neurodevelopmental disease, a physical injury, a neuropsychiatric disease, or a brain cancer.

### Claim 75 (depends on 74)

The protein-drug conjugate of claim 74, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis (ALS), or prion disease (transmissible spongiform encephalopathy).

### Claim 76 (depends on 74)

The protein-drug conjugate of claim 74, wherein the neurodevelopmental disease is Alexander disease, multiple sulfatase deficiency, autism, epilepsy, Rett syndrome, or Fragile X.

### Claim 77 (depends on 74)

The protein-drug conjugate of claim 74, wherein the physical injury is traumatic brain injury, spinal cord injury, stroke, or brain edema.

### Claim 78 (depends on 74)

The protein-drug conjugate of claim 74, wherein the neuropsychiatric disease or disorder is major depressive disorder, anxiety disorder, or bipolar disorder.

### Claim 79 (depends on 74)

The protein-drug conjugate of claim 74, wherein the brain cancer is glioma.

### Claim 80 (depends on 79)

The protein-drug conjugate of claim 79, wherein the glioma is an astrocytoma.

### Claim 81 (depends on 46)

The protein-drug conjugate of claim 46, wherein the molecular cargo comprises a carrier.

### Claim 82 (depends on 81)

The protein-drug conjugate of claim 81, wherein the carrier is a lipid-based carrier.

### Claim 83 (depends on 82)

The protein-drug conjugate of claim 82, wherein the lipid-based carrier is a lipid nanoparticle (LNP), a liposome, a lipidoid, or a lipoplex.

### Claim 84 (depends on 83)

The protein-drug conjugate of claim 83, wherein the lipid-based carrier is a lipid nanoparticle (LNP).

### Claim 85 (depends on 84)

The protein-drug conjugate of claim 84, wherein the LNP further comprises a polynucleotide molecule and/or a polypeptide molecule.

### Claim 86 (depends on 84, 85)

The protein-drug conjugate of claim 84 or 85, wherein the LNP comprises one or more components of a gene editing system.

### Claim 87 (depends on 86)

The protein-drug conjugate of claim 86, wherein the LNP comprises
(a) a Cas nuclease, or a nucleic acid encoding the Cas nuclease, and/or
(b) a guide RNA, or one or more DNAs encoding the guide RNA.

### Claim 88 (depends on 87)

The protein-drug conjugate of claim 87, wherein the Cas nuclease is a Cas9 protein.

### Claim 89 (depends on 88)

The protein-drug conjugate of claim 88, wherein the Cas9 protein is derived from a Streptococcus pyogenes Cas9 protein, a Staphylococcus aureus Cas9 protein, a Campylobacter jejuni Cas9 protein, a Streptococcus thermophilus Cas9 protein, or a Neisseria meningitidis Cas9 protein.

### Claim 90 (depends on 87, 88, 89)

The protein-drug conjugate of any one of claims 87-89, wherein the nucleic acid encoding the Cas nuclease is codon-optimized for expression in a mammalian cell.

### Claim 91 (depends on 90)

The protein-drug conjugate of claim 90, wherein the nucleic acid encoding the Cas nuclease is codon-optimized for expression in a human cell.

### Claim 92 (depends on 87, 88, 89, 90, 91)

The protein-drug conjugate of any one of claims 87-91, wherein the nucleic acid encoding the Cas nuclease is an mRNA.

### Claim 93 (depends on 48, 56)

The protein-drug conjugate of any one of claims 48, 56, and 87-92, wherein the guide RNA is a single guide RNA (sgRNA).

### Claim 94 (depends on 86)

The protein-drug conjugate of claim 86, wherein the LNP comprises a zinc finger nuclease (ZFN), or a transcription activator-like effector nuclease (TALEN).

### Claim 95 (depends on 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94)

The protein-drug conjugate of any one of claims 84-94, wherein the LNP comprises a cationic lipid, a neutral lipid, a helper lipid, a stealth lipid, or any combinations thereof.

### Claim 96 (depends on 95)

The protein-drug conjugate of claim 95, wherein the neutral lipid is distearoylphosphatidylcholine (DSPC).

### Claim 97 (depends on 95)

The protein-drug conjugate of claim 95, wherein the helper lipid is cholesterol.

### Claim 98 (depends on 95)

The protein-drug conjugate of claim 95, wherein the stealth lipid is PEG2k-DMG.

### Claim 99 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

A pharmaceutical composition comprising the protein-drug conjugate of any one of claims 1-98 and a pharmaceutically acceptable carrier.

### Claim 100 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99)

A composition or kit comprising the protein-drug conjugate of any one of claims 1-98 or pharmaceutical composition of claim 99 and a further therapeutic agent.

### Claim 101 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

A complex comprising the protein-drug conjugate of any one of claims 1-98 bound to fibroblast growth factor receptor 3 (FGFR3).

### Claim 102 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98)

A method for making a protein-drug conjugate of any one of claims 1-98 comprising:
(a) contacting the antigen-binding protein, with the molecular cargo under the conditions favorable for conjugation of the antigen-binding protein to the molecular cargo; and
(b) optionally, isolating the protein-drug conjugate produced in step (a).

### Claim 103 (depends on 60, 61, 62, 63, 64, 65, 66, 67, 68)

A method for making a protein-drug conjugate of any one of claims 60-68, wherein the molecular cargo comprises a polypeptide molecule, comprising:
(a) culturing a host cell comprising a polynucleotide encoding the protein-drug conjugate under conditions that allow expression of the protein-drug conjugate; and
(b) optionally, isolating the protein-drug conjugate produced in step (a).

### Claim 104 (depends on 102, 103)

A protein-drug conjugate which is produced by or obtainable by the method of claim 102 or 103.

### Claim 105 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 104)

A vessel or injection device comprising the protein-drug conjugate of any one of claims 1-98 and 104.

### Claim 106 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 104)

A method for administering the protein-drug conjugate of any one of claims 1-98 and 104 to a subject comprising introducing the protein-drug conjugate into the body of the subject.

### Claim 107 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 99, 104)

A method for delivering a molecular cargo to a tissue or cell type expressing FGFR3 in the body of a subject comprising administering to the subject the protein-drug conjugate of any one of claims 1-98 and 104 or the pharmaceutical composition of claim 99.

### Claim 108 (depends on 107)

The method of claim 107, wherein the tissue is brain, spinal cord, or eye.

### Claim 109 (depends on 107)

The method of claim 107, wherein the cell type is astrocyte or astrocyte-derived tumor cell.

### Claim 110 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77, 78, 79, 80, 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95, 96, 97, 98, 104)

A method for treating or preventing a neurological disease or disorder in a subject in need thereof comprising administering to the subject an effective amount of the protein-drug conjugate of any one of claims 1-98 and 104.

### Claim 111 (depends on 110)

The method of claim 110, wherein the neurological disease or disorder is associated with astrocytes.

### Claim 112 (depends on 110, 111)

The method of claim 110 or 111, wherein the neurological disease or disorder is a neurodegenerative disease, neurodevelopmental disease, physical injury, neuropsychiatric disease, or a brain cancer.

### Claim 113 (depends on 112)

The method of claim 112, wherein the neurodegenerative disease is Alzheimer's disease, Parkinson's disease, Huntington's disease, amyotrophic lateral sclerosis, or prion disease (transmissible spongiform encephalopathy).

### Claim 114 (depends on 112)

The method of claim 112, wherein the neurodevelopmental disease is an Alexander disease, multiple sulfatase deficiency, autism, epilepsy, Rett syndrome, or Fragile X.

### Claim 115 (depends on 112)

The method of claim 112, wherein the physical injury is traumatic brain injury, spinal cord injury, stroke, or brain edema.

### Claim 116 (depends on 112)

The method of claim 112, wherein the neuropsychiatric disease or disorder is major depressive disorder, anxiety disorder, or bipolar disorder.

### Claim 117 (depends on 112)

The method of claim 112, wherein the brain cancer is glioma.

### Claim 118 (depends on 117)

The method of claim 117, wherein the glioma is an astrocytoma.

### Claim 119 (depends on 110, 111, 112, 113, 114, 115, 116, 117, 118)

The method of any one of claims 110-118, further comprising administering an additional treatment to the subject.

### Claim 120 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The method of any one of claims 106-119, wherein the protein-drug conjugate is administered into the body of the subject via intrathecal, intracisternal, intracerebroventricular, or intraparenchymal administration into the central nervous system.

### Claim 121 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The method of any one of claims 106-119, wherein the protein-drug conjugate is administered into the body of the subject via intravitreal or intraocular administration into the eye.

### Claim 122 (depends on 106, 107, 108, 109, 110, 111, 112, 113, 114, 115, 116, 117, 118, 119)

The method of any one of claims 106-119, wherein the protein-drug conjugate is administered into the body of the subject via systemic administration.

### Claim 123 (depends on 122)

The method of claim 122, wherein the protein-drug conjugate is administered into the body of the subject via intranasal administration.
